NF-κB signaling is accepted as an oncogenic pathway; however, targeting NF-κB by bortezomib failed to prolong patient survival times in a recent clinical trial, including patients with glioma, melanoma, and lymphoma (32). This evidence concerns the gene NFKB1 and central nervous system cancer.